1.66
0.01 (0.61%)
| 前收盘价格 | 1.65 |
| 收盘价格 | 1.64 |
| 成交量 | 42,122 |
| 平均成交量 (3个月) | 64,767 |
| 市值 | 42,164,784 |
| 价格/销量 (P/S) | 256.05 |
| 股市价格/股市净资产 (P/B) | 2.97 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2025 - 8 Aug 2025 |
| 营业利益率 (TTM) | -37,468.63% |
| 稀释每股收益 (EPS TTM) | 3.38 |
| 季度收入增长率 (YOY) | -51.70% |
| 季度盈利增长率 (YOY) | -19.50% |
| 总债务/股东权益 (D/E MRQ) | 26.43% |
| 流动比率 (MRQ) | 2.45 |
| 营业现金流 (OCF TTM) | -19.88 M |
| 杠杆自由现金流 (LFCF TTM) | -11.33 M |
| 资产报酬率 (ROA TTM) | -135.82% |
| 股东权益报酬率 (ROE TTM) | -485.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Serina Therapeutics, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | -5.0 |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.56 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 63.85% |
| 机构持股比例 | 3.37% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Waverly Advisors, Llc | 30 Jun 2026 | 67,492 |
| Keel Point, Llc | 30 Jun 2026 | 21,508 |
| Avidian Wealth Enterprises, Llc | 30 Sep 2026 | 18,800 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合